Tepid 4Q for Indian firms amid ANDA trickle, currency woes?
This article was originally published in Scrip
Fourth quarter earnings seasons in India may by and large be a lukewarm affair, with a slowdown in the number of ANDA approvals, currency headwinds and continuing FDA scrutiny at domestic sites expected to rein in growth across a clutch of Indian firms.
You may also be interested in...
Dr Reddy’s signals a sharp step up in ambitions at home, propelled by building leadership in 10 therapy segments and an “India-first” approach for specialty products. Uptick in the China business and the potential launch of a Russia-partnered COVID-19 vaccine were other aspects of the business discussed at JPM.
Cipla sees an incremental revenue opportunity of up to $500m for its US franchise by fiscal 2025 and expects to propel growth with strong execution of its complex generics pipeline. The company is also beginning to “lay the blueprint” in China and Brazil, it said at the J.P. Morgan Healthcare Conference.
The new leader at Boehringer Ingelheim India has a full plate and significant expectations riding on her to sustain momentum at one of the fastest-growing foreign pharma firms in the country.